Devasted1,
I don't think we will see additional information for your study. The primary purpose of it : To assess the immune response within prostate tissue following neoadjuvant treatment with sipuleucel-T ( Provenge).
www.clinicaltrials.gov/ct2/show/NCT00715104?term=neoact+provenge&rank=1What was published that
researchers observed a greater than ≥3-fold increase in mean total T cells (CD3-positive), T helper cells (CD3-positive/CD4-positive), and cytotoxic T cells (CD3-positive/CD8-positive) at the radical prostatectomy tumor interface compared with levels of those T cells from the biopsy, radical prostatectomy tumor, and radical prostatectomy benign tumor. Also observed was a progressive increase in memory B-cells (CD20+CD27+IgD-CD86+; pre- and post-culture) and activated mature B-cells (CD20+CD27+IgD+CD86+; post-culture) following the first infusion of PROVENGE. Activated T-cell-associated cytokines were significantly elevated (TNF-α, P < 0.001; IFN-γ, P < 0.001; and IL-2, P < 0.001) in the second and third PROVENGE doses. From last year AUA 2013 was interesting poster
"OPTIMAL TIMING FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC):SEQUENCING AND IDENTIFYING PARAMETERS OF EARLY PROGRESSION WITH SIPULEUCEL-T, that evaluate Provenge from different trials ( including your trial NeoACT NCT00715104 ) by Dr. E.D. Crawford, Dr. A.S.Kibel, Dr. N.D. Shore.
"Conclution:Evidence suggests that sipuleucel-T should be given early in the mCRPC disease course, when disease burden is lower, disease kinetics are less aggressive, and immunocompetence is less affected. The non-overlapping MOA, short treatment course, and manageable adverse event profile of sipuleucel-T accommodates follow-on therapy with either abiraterone acetate, docetaxel, or other agents."epostersonline.s3.amazonaws.com/aua2013/aua2013.0460133.NORMAL.pdfVery interesting abstracts were presented this AUA 2014 that took place in the end January. I will post it on Provenge threat. I hope like you that more doctors will offer Provenge and after 4 years on the market they will not look at this treatment like something " exotic, out of space".
Like Today example:
"Leading Kansas Urology Hospital Extends latest Provenge Treatment for Advanced Prostate Cancer KCUC is now one of the exclusive providers of the latest Provenge treatment for patients suffering from advanced prostate cancer.
Overland Park, KS (marketpressrelease) February 19, 2014 - Leading Kansas urology care hospital KCUC has announced to extend state of the art Provenge treatment for advanced Prostate Cancer issues. It is the first accredited immunotherapy treatment for those in the final stages of the disease.
"We are glad to announce that KCUC is now one of the exclusive providers of the cutting edge Provenge prostate cancer treatment in Kansas. The treatment counts on the patient's immune system to help in fighting the critical disease", reported a seasoned urology specialist from the hospital.
Clinical studies have proved that Provenge enables the cancer patients to survive longer, at least by 3 years, in comparison to men treated otherwise. "You don't have to worry much about the side-effects as Provenge begets some really mild kicks that won't last beyond 2 days. The side kicks here include common conditions like headache, joint ache, nausea, back pain, fever, fatigue and chills. The best part is that Provenge therapy just takes a month to complete with just 3 infusions."www.marketpressrelease.com/Leading-Kansas-Urology-Hospital-Extends-latest-Provenge-Treatment-for-Advanced-Prostate-Cancer-1392815931.html or like it:
"Published on February 18, 2014
Avera Cancer Institute Approved To Offer Comprehensive PROVENGE® (sipuleucel-T) Treatment
Avera is the only site in the region to offer this therapy, offering hope for men with advanced prostate cancer"
www.avera.org/experience/shared/releases/news/2014/provenge2014/ Just in that time when I try to posted it I read RobertC' post about
article from PC Foundation about
form of immunotherapy in development. They started
"February 18, 2014 -- The journal Science, anointed advances in cancer immunotherapy as the 2013 Breakthrough of the Year –the “It” science story."
How future bright for immunotherapy and no One word about
Provenge!
Shame on Prostate Cancer Fundation for it and for its war no only against Provenge but for me it is war against Prostate cancer patients and hundreds thousands Innocent victims of this terrible disease who died and never had chance to receive Provenge.
Shame on PCF !My best to you Hope
Post Edited (HOPENEVERDIE) : 2/19/2014 1:04:22 PM (GMT-7)